Tag - DTCFF

Defence Therapeutics (CSE:DTC; OTCQB:DTCFF; FSE:DTC) announced that it has received a “no objection letter” (NOL) from Health Canada authorizing the company to proceed with a Phase I trial of intratumoral administration...